Moderna
-
Moderna’s mRNA Platform Enables Rapid Personalized Cancer Vaccines
By sequencing individual tumors to target unique neoantigens, Moderna’s platform creates bespoke vaccines in nine weeks, cutting melanoma recurrence risk by 42%.
-
How Personalized mRNA Vaccines Target Neoantigens to Beat Melanoma
Discover how custom mRNA cancer vaccines train the immune system against tumor neoantigens to prevent melanoma recurrence compared to standard adjuvant therapy.
Most read
-
Minnesota Makes Personal Finance Course Mandatory for High School Graduation
-
UK Households With £10,000 Risk Losing £300 To Low Interest Rates
-
Selangor International Care Expo in Kuala Lumpur 2026
-
Asian & Oceanian Epilepsy Congress 2026 in Kuala Lumpur
-
Baby & Beyond Maternity Expo in Kuala Lumpur 2026
-
Amgen and AstraZeneca Combination Therapy Shows Unprecedented Survival Gains in Lung Cancer
-
Moderna’s mRNA Platform Enables Rapid Personalized Cancer Vaccines
-
Evaluating Skyrizi’s Efficacy and Market Position in Crohn’s Disease Care
-
How Personalized mRNA Vaccines Target Neoantigens to Beat Melanoma
-
Understanding How Novel Drug Targets Aim to Slow Alzheimer’s
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Dennis Lo Pioneers Liquid Biopsy for Cancer and Prenatal Testing
-
New Research Highlights Rising Internet Addiction Debate
-
Study Suggests Drinking Water With Meals May Lead To Overeating
-
Real-World Oncotype DX Adoption: Rates and Key Challenges
-
Energy Drinks: Youth Marketing, Caffeine Risks Under Scrutiny
-
ADHD Dopamine Dysfunction Disrupts Sleep-Wake Cycles, Study Finds